Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian carcinoma

European Journal of Cancer

Volumn 36, Issue 7, 2000, Pages 817-820

  Pignata, S ^a   Monfardini, S ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; PACLITAXEL;

ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; META ANALYSIS; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DECISION MAKING; FEMALE; HUMANS; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 0034104068     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00050-2     Document Type: Article

References (28)

1. Olshansky S.J., Carnes B.A., Cassel C.K. The ageing of the human species. Sci. Am. 268:1993;46-52.
2. La Vecchia C., Lucchini F., Negri E.et al. Trends of cancer mortality in Europe 1955-89. breast and genital sites Eur. J. Cancer. 28A:1992;927-998.
3. Jensen O.M., Esteve J., Moller H.et al. Cancer in Europe Community and its members states. Eur. J. Cancer. 26A:1990;1167-1256.
4. Riggs J.E. Rising ovarian cancer mortality in the elderly. a manifestation of differential survival Gynecol. Oncol. 58:1995;64-67.
5. Hightower R.D., Nguyen H.N., Averette H.E.et al. National survey of ovarian carcinoma IV. patterns of care and related survival for older patients Cancer. 73:1994;377-383.
6. Ries L.A.G. Ovarian cancer. Survival and treatment differences by age. Cancer. 71:1993;254-259.
7. Berchuck A., Kohler M., Boente M.P.et al. Growth regulation and transformation of ovarian epithelium. Cancer. 71:1993;545-551.
8. Grover S.A., Cook E.F., Adam J.et al. Delayed diagnosis of gynecologic tumors in elderly women. relation to national medical practice patterns Am. J. Med. 86:1989;151-157.
9. Kirschner C.V., DeSerto T.M., Isaacs J.H.et al. Surgical treatment of the elderly patient with gynecologic cancer. Surg. Gynecol. Obstet. 170:1990;379-384.
10. Yancik R., Moore T.D., Martin G.et al. Older women as the focus for research and treatment of ovarian cancer. Cancer. 71:1993;514-516.
11. Balducci L., Parker M., Sexton W.et al. Pharmacology of antineoplastic agents in the elderly patient. Semin. Oncol. 16:1989;76-84.
12. Alberts D.S., Dahlberg S., Green S.J.et al. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. Cancer. 71:1993;618-627.
13. Thigpen T., Brady M.F., Omura G.A.et al. Age as prognostic factor in ovarian carcinoma. Cancer. 71:1993;606-614.
14. Edmonson J.H., Su J., Krook J.E. Treatment of ovarian cancer in elderly women. Cancer. 71:1993;615-617.
15. Markman M., Lewis J.L., Saigo P.et al. Epithelial ovarian cancer in the elderly. Cancer. 71:1993;634-637.
16. Trimble E.L., Cain D., Carter C.L.et al. Representation of the elderly on cancer clinical trials. Proc. Ann. Meet. Am. Soc. Clin. Oncol. 13:1994;527.
17. Monfardini S., Repetto L., Zagonel Y.et al. Guidelines for the management of cancer in the elderly. EORTC study group on neoplasia in the elderly. Crit. Rev. Oncol. Hematol. 27:1998;85-87.
18. Monfardini S., Ferrucci L., Fratino L.et al. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer. 77:1996;395-401.
19. Parmar M.K.B., Torri V., Bonaventura A.et al. ICON2. randomised trial of single agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer Lancet. 352(9140):1998;1571-1576.
20. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia. Lancet. 2(8555):1987;353-359.
21. Skarlos D.V., Aravantinos G., Kosmidis P.et al. Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer. a Hellanic cooperative oncology group study Eur. J. Cancer. 32A:1996;421-428.
22. Muggia F.M., Braly P.S., Brady M.F.et al. Proc Ann. Meet. Am. Soc. Clin. Oncol. 16:1997;A1257.
23. Cornelison T.L., Reed E. Dose intensity of high-dose carboplatin in refractory ovarian carcinoma relative to age. Cancer. 71:1993;650-655.
24. Gridelli C., Perrone F., Gallo C.et al. on the behalf of ELVIS group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J. Natl. Cancer Inst. 91:1999;66-72.
25. Fennelly D., Aghajanian C., Shapiro F.et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J. Clin. Oncol. 15:1997;187-192.
26. Trope C., Sorbe B., Simonsen E.et al. A phase II, non-randomized study of single-agent paclitaxel (Taxol) in patients with previously untreated FIGO stage III, suboptimally resected ovarian cancer. a preliminary report Int. J. Gynecol. Cancer. 43:1994;7-12.
27. Gore M.E., Rustin G., Slevin M.et al. Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. London Gynaecological Oncology and North Thames Gynaecological Oncology Groups. Br. J. Cancer. 75:1997;710-714.
28. Bicher A., Sarosy G., Kohn E.et al. Age does not influence taxol dose intensity in recurrent carcinoma of the ovary. Cancer. 71:1993;594-600.